Welcome to our dedicated page for Immix Biopharma news (Ticker: IMMX), a resource for investors and traders seeking the latest updates and insights on Immix Biopharma stock.
Immix Biopharma, Inc. develops clinical-stage cell therapies focused on relapsed/refractory AL Amyloidosis, led by NXC-201, a sterically optimized BCMA-targeted CAR-T therapy. Company news commonly covers NXC-201 clinical data from the NEXICART-2 study, FDA designations such as Breakthrough Therapy, RMAT and orphan-drug status, and regulatory-development planning.
Updates also include equity financings, pre-funded warrants, private placements, investor-conference participation, and commercial and medical leadership additions tied to the company’s rare-disease oncology and hematology strategy.
Immix Biopharma, Inc. (Nasdaq: IMMX) has priced its initial public offering (IPO) at $5.00 per share, aiming to raise $21 million before expenses. The offering consists of 4,200,000 shares, with an additional 630,000 shares available for overallotments. Trading on Nasdaq is set to begin on December 16, 2021, with the offering closing on December 20, 2021. Proceeds will fund a Phase 2a trial for IMX-110 in soft tissue sarcoma, a Phase 1b trial, and other corporate purposes. ThinkEquity is the sole book-running manager for this offering.